Tools

LEADER 03302nam a2200589 i 4500

001 on1425135627;

003 OCoLC;

005 20240306101513.0;

006 m o d f ;

007 cr b|||||a||||;

008 240306s2024 dcua ob f000 0 eng c;

024 8 a| 52-490q| (GPO jacket number);

035 a| (Sirsi) o1425135627;

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

074 a| 1019-C-01 (online);

086 0 a| Y 4.C 73/8:118-7;

245 14 a| The federal response to COVID-19 :b| joint hearing before the Subcommittee on Oversight and Investigations and the Subcommittee on Health of the Committee on Energy and Commerce, One Hundred Eighteenth Congress, first session, February 8, 2023.;

264 1 a| Washington :b| U.S. Government Publishing Office,c| 2024.;

300 a| 1 online resource (vi, 250 pages) :b| color illustrations;

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

504 a| Includes bibliographical references.;

511 0 a| Hearing witnesses: Lawrence A. Tabak, D.D.S., Ph.D., Senior Official Performing the Duties of Director, National Institutes of Health; Answers to submitted questions \1\ Rochelle P. Walensky, M.D., Director, Centers for Disease Control and Prevention; Answers to submitted questions \1\ Robert M. Califf, M.D., Commissioner, Food and Drug Administration, Department of Health and Human Services.;

518 a| Date of hearing: 2023-02-08.;

588 a| Description based on online resource, PDF version; title from title page (GovInfo, viewed March 6, 2024).;

500 a| In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).;

500 a| GPO Cataloging Record Distribution Program (CRDP).;

650 0 a| COVID-19 (Disease)z| United States.=| ^A1407776;

650 0 a| COVID-19 Pandemic, 2020-2023z| United States.=| ^A1418885;

650 0 a| Communication in politics.=| ^A76520;

650 0 a| Conspiracy theories.=| ^A1042779;

650 0 a| Communication in public health.=| ^A685092;

650 0 a| Disinformationz| United States.=| ^A279626;

650 0 a| Misinformationz| United States.=| ^A1448831;

650 0 a| Communicable diseases.=| ^A824;

650 0 a| Coronavirus infectionsz| United Statesx| Prevention.=| ^A828712;

650 7 a| Health.2| cgpa;

650 7 a| Government Operations and Politics.2| cgpa;

655 7 a| Legislative hearings.2| lcgft;

776 08 i| Print version:a| United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.t| Federal response to COVID-19w| (OCoLC)1425134876;

856 40 u| https://purl.fdlp.gov/GPO/gpo2231547| 0;

922 a| BIBCONEWb| 20240306;

949 a| Click on web addressw| asish| joyner94;

596 a| 1;

998 a| 6339872;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6339872-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 4/15/2024x| EDOCUMENTz| JERESOURCE;

The federal response to COVID-19 : joint hearing before the Subcommittee on Oversight and Investigations and the Subcommittee on Health of the Committee on Energy and Commerce, One Hundred Eighteenth Congress, first session, February 8, 2023.

Author/creator	United States
Other author	United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health, author.
Format	Electronic
Publication	Washington : U.S. Government Publishing Office, 2024.
Description	1 online resource (vi, 250 pages) : color illustrations
Supplemental Content	https://purl.fdlp.gov/GPO/gpo223154
Subjects	COVID-19 (Disease)--United States. COVID-19 Pandemic, 2020-2023--United States. Communication in politics. Conspiracy theories. Communication in public health. Disinformation--United States. Misinformation--United States. Communicable diseases. Coronavirus infections--United States. --Prevention.

General note	In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).
General note	GPO Cataloging Record Distribution Program (CRDP).
Bibliography note	Includes bibliographical references.
Performer	Hearing witnesses: Lawrence A. Tabak, D.D.S., Ph.D., Senior Official Performing the Duties of Director, National Institutes of Health; Answers to submitted questions \1\ Rochelle P. Walensky, M.D., Director, Centers for Disease Control and Prevention; Answers to submitted questions \1\ Robert M. Califf, M.D., Commissioner, Food and Drug Administration, Department of Health and Human Services.
Date/time/place of a event note	Date of hearing: 2023-02-08.
Source of description	Description based on online resource, PDF version; title from title page (GovInfo, viewed March 6, 2024).
Issued in other form	Print version: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. Federal response to COVID-19
Genre/form	Legislative hearings.
Standard identifier#	52-490 (GPO jacket number)
GPO item number	1019-C-01 (online)
Govt. docs number	Y 4.C 73/8:118-7

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

The federal response to COVID-19 : joint hearing before the Subcommittee on Oversight and Investigations and the Subcommittee on Health of the Committee on Energy and Commerce, One Hundred Eighteenth Congress, first session, February 8, 2023.

Click here for more information about this title

Availability